HK1083498A1 - Pyrrolidone derivatives as maob inhibitors - Google Patents

Pyrrolidone derivatives as maob inhibitors

Info

Publication number
HK1083498A1
HK1083498A1 HK06103475A HK06103475A HK1083498A1 HK 1083498 A1 HK1083498 A1 HK 1083498A1 HK 06103475 A HK06103475 A HK 06103475A HK 06103475 A HK06103475 A HK 06103475A HK 1083498 A1 HK1083498 A1 HK 1083498A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolidone derivatives
maob inhibitors
maob
inhibitors
pyrrolidone
Prior art date
Application number
HK06103475A
Other languages
English (en)
Inventor
Iding Hans
Jolidon Synese
Krummenacher Daniela
Rodriguez Sarmiento Rosa Maria
Thomas Andrew William
Wirz Beat
Wostl Wolfgang
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1083498A1 publication Critical patent/HK1083498A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK06103475A 2002-09-20 2006-03-20 Pyrrolidone derivatives as maob inhibitors HK1083498A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010356 WO2004026825A1 (en) 2002-09-20 2003-09-18 Pyrrolidone derivatives as maob inhibitors

Publications (1)

Publication Number Publication Date
HK1083498A1 true HK1083498A1 (en) 2006-07-07

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06103475A HK1083498A1 (en) 2002-09-20 2006-03-20 Pyrrolidone derivatives as maob inhibitors
HK06103476.1A HK1083499A1 (en) 2002-09-20 2006-03-20 Pyrrolidone derivatives as maob inhibitors
HK06103481A HK1084383A1 (en) 2002-09-20 2006-03-20 4-pyrrolidino-phenyl-bezyl ether derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK06103476.1A HK1083499A1 (en) 2002-09-20 2006-03-20 Pyrrolidone derivatives as maob inhibitors
HK06103481A HK1084383A1 (en) 2002-09-20 2006-03-20 4-pyrrolidino-phenyl-bezyl ether derivatives

Country Status (32)

Country Link
US (4) US7151111B2 (de)
EP (3) EP1542970B1 (de)
JP (3) JP4335141B2 (de)
KR (3) KR100681586B1 (de)
CN (3) CN100383118C (de)
AR (3) AR041298A1 (de)
AT (2) ATE472530T1 (de)
AU (3) AU2003273901B2 (de)
BR (4) BR0314314A (de)
CA (3) CA2498335A1 (de)
CY (1) CY1110745T1 (de)
DE (2) DE60331559D1 (de)
DK (1) DK1542970T3 (de)
ES (2) ES2344557T3 (de)
GT (3) GT200300205A (de)
HK (3) HK1083498A1 (de)
HR (3) HRP20050263B1 (de)
JO (2) JO2605B1 (de)
MX (3) MXPA05002878A (de)
MY (3) MY134480A (de)
NO (3) NO329754B1 (de)
NZ (3) NZ538046A (de)
PA (3) PA8583001A1 (de)
PE (3) PE20050077A1 (de)
PL (3) PL376018A1 (de)
PT (1) PT1542970E (de)
RU (3) RU2323209C2 (de)
SI (1) SI1542970T1 (de)
TW (3) TWI286132B (de)
UY (3) UY27990A1 (de)
WO (3) WO2004026825A1 (de)
ZA (3) ZA200501137B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 b 억제제로서 벤질옥시 유도체
US7456210B2 (en) * 2004-08-02 2008-11-25 Hoffmann-La Roche Inc. Benzyloxy derivatives
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
CN101142181B (zh) * 2005-03-15 2011-05-04 弗·哈夫曼-拉罗切有限公司 对映异构纯的4-吡咯烷子基苯基苄基醚衍生物的制备方法
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
KR20150127172A (ko) 2013-03-14 2015-11-16 다트 뉴로사이언스 (케이만) 엘티디. Mao 억제제로서 치환된 나프티리딘 및 퀴놀린 화합물
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
KR20160067208A (ko) 2013-10-29 2016-06-13 에프. 호프만-라 로슈 아게 알츠하이머 병의 치료에 유용한 피롤리돈 유도체의 결정 형태 및 이의 제조
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
CN107223052A (zh) * 2015-03-27 2017-09-29 豪夫迈·罗氏有限公司 包含sembragiline的药物制剂
EP3689870B1 (de) 2017-09-27 2022-07-13 Kagoshima University Analgetikum unter verwendung eines pac1-rezeptor-antagonisten-arzneimittels
EP3691634A4 (de) 2017-10-05 2021-03-31 Biogen Inc. Verfahren zur herstellung von alpha-carboxamid-pyrolidin-derivaten
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CA3092747A1 (en) 2018-03-08 2019-09-12 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
US20220184081A1 (en) 2019-02-27 2022-06-16 Kagoshima University Antipruritic agent using pac1 receptor antagonist
JP7049637B1 (ja) 2020-05-08 2022-04-07 国立大学法人 鹿児島大学 Pac1受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
ES2087097T3 (es) 1989-04-19 1996-07-16 Otsuka Pharma Co Ltd Derivados de acidos fenilcarboxilicos que contienen un heterociclo.
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CN1116870C (zh) 1996-03-15 2003-08-06 萨默塞特药品有限公司 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
AU4181000A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US7621863B2 (en) * 2000-02-10 2009-11-24 Obtech Medical Ag Urinary incontinence treatment with wireless energy supply
EP1255513B1 (de) * 2000-02-14 2005-05-25 Potencia Medical AG Penisprothese
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
AR041298A1 (es) 2005-05-11
BR0314631A (pt) 2005-08-02
TWI286132B (en) 2007-09-01
ZA200501557B (en) 2005-09-08
PE20050077A1 (es) 2005-03-01
NO330012B1 (no) 2011-02-07
WO2004026827A1 (en) 2004-04-01
TW200413350A (en) 2004-08-01
CA2498335A1 (en) 2004-04-01
CN100400509C (zh) 2008-07-09
DE60331559D1 (de) 2010-04-15
BRPI0314631B1 (pt) 2018-04-17
KR100681586B1 (ko) 2007-02-09
NO20050701L (no) 2005-03-02
US7151111B2 (en) 2006-12-19
WO2004026825A1 (en) 2004-04-01
TWI337604B (en) 2011-02-21
HK1084383A1 (en) 2006-07-28
NZ538049A (en) 2007-05-31
HK1083499A1 (en) 2006-07-07
MXPA05002878A (es) 2005-05-27
CN1681777A (zh) 2005-10-12
US20040116707A1 (en) 2004-06-17
MY134480A (en) 2007-12-31
HRP20050263B1 (hr) 2013-09-30
EP1542971A1 (de) 2005-06-22
HRP20050263A2 (en) 2006-12-31
EP1542969A1 (de) 2005-06-22
AU2003267381B2 (en) 2009-08-27
AU2003270213B8 (en) 2009-03-05
RU2323209C2 (ru) 2008-04-27
GT200300206A (es) 2004-04-29
BR0314299A (pt) 2005-12-13
RU2005111968A (ru) 2006-11-10
NO20050665L (no) 2005-04-18
US7235581B2 (en) 2007-06-26
US7037935B2 (en) 2006-05-02
KR20050057456A (ko) 2005-06-16
TW200410935A (en) 2004-07-01
MY135696A (en) 2008-06-30
CY1110745T1 (el) 2015-06-10
JP2006510596A (ja) 2006-03-30
RU2005111969A (ru) 2006-01-20
ZA200501311B (en) 2006-10-25
AU2003273901B2 (en) 2008-07-10
TWI331994B (en) 2010-10-21
KR20050057466A (ko) 2005-06-16
JP4335142B2 (ja) 2009-09-30
EP1542969B1 (de) 2010-03-03
EP1542970A1 (de) 2005-06-22
PA8583501A1 (es) 2004-04-23
PE20050079A1 (es) 2005-03-01
GT200300205A (es) 2004-04-29
PT1542970E (pt) 2010-07-19
PL376021A1 (en) 2005-12-12
UY27993A1 (es) 2004-03-31
JP2006503833A (ja) 2006-02-02
PA8583001A1 (es) 2004-04-23
DE60333202D1 (de) 2010-08-12
AU2003270213B2 (en) 2009-02-12
BR0314314A (pt) 2005-07-26
ATE459601T1 (de) 2010-03-15
US20060122235A1 (en) 2006-06-08
KR100676014B1 (ko) 2007-01-30
AR041299A1 (es) 2005-05-11
CA2496756A1 (en) 2004-04-01
JP4335140B2 (ja) 2009-09-30
AU2003273901A1 (en) 2004-04-08
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
HRP20050262A2 (en) 2006-06-30
RU2336267C2 (ru) 2008-10-20
CN1681779A (zh) 2005-10-12
CN100503562C (zh) 2009-06-24
PA8583601A1 (es) 2004-09-16
CN1681778A (zh) 2005-10-12
ES2344557T3 (es) 2010-08-31
JO2605B1 (en) 2011-11-01
GT200300204A (es) 2004-04-29
SI1542970T1 (sl) 2010-08-31
KR20050057450A (ko) 2005-06-16
TW200408624A (en) 2004-06-01
CA2498785A1 (en) 2004-04-01
RU2336268C2 (ru) 2008-10-20
WO2004026826A1 (en) 2004-04-01
JO2604B1 (en) 2011-11-01
UY27991A1 (es) 2004-03-31
NO329754B1 (no) 2010-12-13
ES2338646T3 (es) 2010-05-11
NZ538046A (en) 2007-08-31
US20040097578A1 (en) 2004-05-20
US7122562B2 (en) 2006-10-17
US20040106650A1 (en) 2004-06-03
ZA200501137B (en) 2006-12-27
AU2003270213A1 (en) 2004-04-08
HRP20050261A2 (en) 2006-05-31
JP2006503834A (ja) 2006-02-02
AU2003267381A1 (en) 2004-04-08
PL376018A1 (en) 2005-12-12
NZ538048A (en) 2007-05-31
NO20050652L (no) 2005-03-08
MY133332A (en) 2007-11-30
RU2005111974A (ru) 2006-01-20
PE20050078A1 (es) 2005-02-28
AR041297A1 (es) 2005-05-11
PL376019A1 (en) 2005-12-12
DK1542970T3 (da) 2010-08-02
EP1542970B1 (de) 2010-06-30
ATE472530T1 (de) 2010-07-15
JP4335141B2 (ja) 2009-09-30
CN100383118C (zh) 2008-04-23
MXPA05002880A (es) 2005-05-27
KR100676015B1 (ko) 2007-01-30
UY27990A1 (es) 2004-03-31
CA2498785C (en) 2011-07-26
CA2496756C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
HK1083499A1 (en) Pyrrolidone derivatives as maob inhibitors
EG25482A (en) Inhibitors
IL173616A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003300832A8 (en) Nf-kappab inhibitors
EP1489088A4 (de) Neues alpha-amino-n-(diaminophosphinyl)lactamderivat
GB0315870D0 (en) Heterocyclic derivatives
IL172257A0 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
EP1532133A4 (de) Nf-:b-inhibitoren
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
HK1108432A1 (en) Benzyloxy derivatives as maob inhibitors
AU2003224941A8 (en) Nf-kappab inhibitors
GB2403474B (en) Amide derivatives
AU2003235889A8 (en) Amide derivatives
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB2388841B (en) Polymerisable heterocyclic acetylenes
GB0226609D0 (en) Heterocyclic derivatives
HRP20050156A2 (en) Pyrrolidine derivatives as tryptase inhibitors
GB0311957D0 (en) Heterocyclic derivatives
IL169094A0 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors
GB0208094D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors
GB0224102D0 (en) Inhibitors
GB0217330D0 (en) Inhibitors
GB0207491D0 (en) Inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190914